[1] Huang D Q, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 37-49.

[2] Gao W, Zhu Y, Ye J, et al. Gut non-bacterial microbiota contributing to alcohol-associated liver disease
[J]. Gut Microbes, 2021, 13(1): 1984122.

[3] Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy
[J]. J Hepatol, 2020, 72(3): 558-577.

[4] Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis
[J]. Trends Mol Med, 2021, 27(9): 844-855.

[5] Posteraro B, Paroni Sterbini F, Petito V, et al. Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats
[J]. Alcohol Clin Exp Res, 2018, 42(12): 2313-2325.

[6] Bluemel S, Wang L, Kuelbs C, et al. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice
[J]. Gut Microbes, 2020, 11(3): 265-275.

[7] Bajaj J S. Alcohol, liver disease and the gut microbiota
[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246.

[8] Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future
[J]. Cell Host Microbe, 2020, 28(2): 233-244.

[9] Szabo G. Gut-liver axis in alcoholic liver disease
[J]. Gastroenterology, 2015, 148(1): 30-6.

[10] Chopyk D M, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
[J]. Gastroenterology, 2020, 159(3): 849-863.

[11] Adolph T E, Grander C, Moschen A R, et al. Liver-Microbiome Axis in Health and Disease
[J]. Trends Immunol, 2018, 39(9): 712-723.

[12] Peay K G, Kennedy P G, Talbot J M. Dimensions of biodiversity in the Earth mycobiome
[J]. Nat Rev Microbiol, 2016, 14(7): 434-47.

[13] Nash A K, Auchtung T A, Wong M C, et al. The gut mycobiome of the Human Microbiome Project healthy cohort
[J]. Microbiome, 2017, 5(1): 153.

[14] Hillman E T, Lu H, Yao T, et al. Microbial Ecology along the Gastrointestinal Tract
[J]. Microbes Environ, 2017, 32(4): 300-313.

[15] Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents
[J]. PLoS One, 2013, 8(6): e66019.

[16] Willis K A, Purvis J H, Myers E D, et al. Fungi form interkingdom microbial communities in the primordial human gut that develop with gestational age
[J]. FASEB J, 2019, 33(11): 12825-12837.

[17] Schei K, Avershina E, Oien T, et al. Early gut mycobiota and mother-offspring transfer
[J]. Microbiome, 2017, 5(1): 107.

[18] Auchtung T A, Fofanova T Y, Stewart C J, et al. Investigating Colonization of the Healthy Adult Gastrointestinal Tract by Fungi
[J]. mSphere, 2018, 3(2).

[19] Hartmann P, Lang S, Zeng S, et al. Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder
[J]. Front Physiol, 2021, 12: 699253.

[20] Lang S, Duan Y, Liu J, et al. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis
[J]. Hepatology, 2020, 71(2): 522-538.

[21] Yang A M, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease
[J]. J Clin Invest, 2017, 127(7): 2829-2841.

[22] Petrasek J, Bala S, Csak T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
[J]. J Clin Invest, 2012, 122(10): 3476-89.

[23] Moyes D L, Wilson D, Richardson J P, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection
[J]. Nature, 2016, 532(7597): 64-8.

[24] Sun S, Wang K, Sun L, et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE(2) to alcoholic hepatic steatosis
[J]. Gut Microbes, 2020, 12(1): 1830693.

[25] Shkoporov A N, Clooney A G, Sutton T D S, et al. The Human Gut Virome Is Highly Diverse, Stable, and Individual Specific
[J]. Cell Host Microbe, 2019, 26(4): 527-541 e5.

[26] Gregory A C, Zablocki O, Zayed A A, et al. The Gut Virome Database Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut
[J]. Cell Host Microbe, 2020, 28(5): 724-740 e8.

[27] Bai G H, Lin S C, Hsu Y H, et al. The Human Virome: Viral Metagenomics, Relations with Human Diseases, and Therapeutic Applications
[J]. Viruses, 2022, 14(2).

[28] Jiang L, Lang S, Duan Y, et al. Intestinal Virome in Patients With Alcoholic Hepatitis
[J]. Hepatology, 2020, 72(6): 2182-2196.

[29] Yurlov K I, Masalova O V, Kisteneva L B, et al. Human Herpesviruses Increase the Severity of Hepatitis
[J]. Biology (Basel), 2021, 10(6).

[30] Tsai J P, Tseng K C, Lin M N, et al. A high seroprevalence of human herpesvirus type 8 already present in patients with chronic hepatitis before the development of cirrhosis
[J]. Pathology, 2019, 51(1): 86-90.

[31] Chou A L, Huang W W, Tsao S M, et al. Human herpesvirus type 8 in patients with cirrhosis: correlation with sex, alcoholism, hepatitis B virus, disease severity, and thrombocytopenia
[J]. Am J Clin Pathol,2008,130(2): 31-7.

[32] Hu J, Zhang X, Yu G, et al. Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis
[J]. BMC Gastroenterol, 2019, 19(1): 94.

[33] Keen E C, Dantas G. Close Encounters of Three Kinds: Bacteriophages, Commensal Bacteria, and Host Immunity
[J]. Trends Microbiol, 2018, 26(11): 943-954.

[34] Bajaj J S, Sikaroodi M, Shamsaddini A, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy
[J]. Gut, 2021, 70(6): 1162-1173.

[35] Pirnay J P, Blasdel B G, Bretaudeau L, et al. Quality and safety requirements for sustainable phage therapy products
[J]. Pharm Res, 2015, 32(7): 2173-9.

[36] Cheroutre H, Madakamutil L. Acquired and natural memory T cells join forces at the mucosal front line
[J]. Nat Rev Immunol, 2004, 4(4): 290-300.

[37] Cheroutre H L F, Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes
[J]. Nat Rev Immunol.

[38] Liu L, Gong T, Tao W, et al. Commensal viruses maintain intestinal intraepithelial lymphocytes via noncanonical RIG-I signaling
[J]. Nat Immunol, 2019, 20(12): 1681-1691.

[39] Gogokhia L, Buhrke K, Bell R, et al. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis
[J]. Cell Host Microbe, 2019, 25(2): 285-299 e8.

[40] European Association for the Study of the Liver. Electronic Address E E E, European Association for the Study of The L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
[J]. J Hepatol, 2018, 69(2): 406-460.

[41] Zeng X, Sheng X, Wang P Q, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis
[J]. Hepatol Int, 2021, 15(1): 155-165.

[42] Wang Z, Hou W, Zhang W, et al.
[Rifaximin improves clinical symptoms and short-term survival in cirrhotic patients with refractory type ascites]
[J]. Zhonghua Gan Zang Bing Za Zhi, 2022, 30(11): 1170-1174.

[43] Fujimoto Y, Kaji K, Nishimura N, et al. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
[J]. World J Gastroenterol, 2021, 27(48): 8323-8342.

[44] Pais P, Almeida V, Yilmaz M, et al. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic?
[J]. J Fungi (Basel), 2020, 6(2).

[45] Kazmierczak-Siedlecka K, Ruszkowski J, Fic M, et al. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases
[J]. Curr Microbiol, 2020, 77(9): 1987-1996.

[46] Wang C, Li W, Wang H, et al. Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF-alpha and IL-6 levels and functions and by rebalancing intestinal microbiota
[J]. BMC Microbiol, 2019, 19(1): 246.

[47] Sjomina O, Polaka I, Suhorukova J, et al. Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation
[J]. Eur J Cancer Prev, 2023.

[48] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
[J]. Nature, 2019, 575(7783): 505-511.

[49] Van Belleghem J D, Clement F, Merabishvili M, et al. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages
[J]. Sci Rep, 2017, 7(1): 8004.

[50] Mendes B G, Duan Y, Schnabl B. Immune Response of an Oral Enterococcus faecalis Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease
[J]. Viruses, 2022, 14(3).

[51] Wang S-Y T X, Liu Z-Q, Ma H, Liu T-B, Yang Y-Q, Ying Y, Gao R-Y, Zhang D-Z, Ma Y-F, Chen K, Lin L, Jiang Z-H, Yu J-L. . Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage PA_LZ7 in a mouse model.
[J]. Microbiol Spectr, 2024, 12(1): e0188223.

[52] Tan X, Chen K, Jiang Z, et al. Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions
[J]. J Virol, 2024, 98(1): e0135923.